EU Panel Backs Higher Dose of Novo Nordisk's Weight-loss Drug Wegovy

09:36 AM EST, 12/12/2025 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of a new 7.2-milligram dose of Novo Nordisk's (NOVO-B.CO) Wegovy, according to a Friday release. The panel's positive opinion is based on the Step Up clinical trial program, which showed that treatment with the 7.2-mg Wegovy, or semaglutide, dose resulted in an average weight loss of 20.7% in people with obesity and without diabetes at 72 weeks, with one in three participants achieving at least a 25% weight loss, while the safety and tolerability profile remained consistent with the approved 2.4-mg dose. The Danish drugmaker noted that the higher dose is also currently under review in the UK, the US and other countries.